Kordbacheh F, Farah CS. Current and emerging molecular therapies for head and neck squamous cell carcinoma. Cancers (Basel). 2021;13(21):5471. Published 2021 Oct 30. doi:10.3390/cancers13215471
Kordbacheh F, Farah CS. Molecular pathways and druggable targets in head and neck squamous cell carcinoma. Cancers (Basel). 2021;13(14):3453. Published 2021 Jul 9. doi:10.3390/cancers13143453
Meara CHO*, Coupland LA*, Kordbacheh F*, et al. Neutralizing the pathological effects of histones with small polyanions. Nat Commun. 2020;11(1):6408. Published 2020 Dec 16. doi:10.1038/s41467-020-20231-y
Kordbacheh F, Carruthers TJ, Bezos A, et al. Promotion of Mammalian Angiogenesis by Neolignans Derived from Soybean Extracellular Fluids. PLoS One. 2018;13(5):e0196843. Published 2018 May 8. doi:10.1371/journal.pone.0196843
Farah CS, Kordbacheh F, John K, Bennett N, Fox SA. Molecular Classification of Autofluorescence Defined Margins in Oral Potentially Malignant Disorders. Oral Dis. 2018;24(5):732-740. doi:10.1111/odi.12818
*Equal first authors
Farzaneh Kordbacheh, Ph.D.
Farzaneh (Farzi) Kordbacheh is a research scientist II in the Golub lab at the Broad Institute of MIT and Harvard. Using single cell genomics, spatial and multiplex assays, and optical screenings, she has led the efforts to identify cellular circuits within and between cells in tissues and tumor microenvironments. In the MIDAS project, she leads the development of novel high-throughput in vivo assays using xenograft models of human cancer cell lines to delineate cancer dependencies in diverse microenvironments and discover novel therapeutic targets.
Kordbacheh was awarded the Gordon Ada Career Advancement Award (2020) from the Australian Society for Immunology, the NHMRC Symposium on Research Translation Award (2019), the Jared Purton Award (2019) from the Australian Society for Immunology, The Biotron Founders Early Career Researcher Award (2019) from JCSMR, ANU, and the Bootes Foundation Seed Funding (2019). She holds the following patents: PCT/AU2017/905024, PCT/AU2019/050156, US2020/16/770987, and US2021/17/43076.
Prior to joining the Broad Institute in 2021, Kordbacheh was a staff scientist in the Melanoma Program at Dana-Farber Cancer Institute, a role to which she advanced from a research fellow in 2020. From 2015 to 2020, Kordbacheh was head of the R&D program for development of small polyanions that can neutralize the pathological effects of neutrophil extracellular traps and their associated histones at the Australian National University. The drugs are currently in clinical trial phase II for sepsis and COVID-19. During her postdoctoral studies in the Oral Oncology Research Program at the University of Queensland Centre for Clinical Research, she focused on transcriptome analysis of pre-cancerous and malignant oral lesions in order to identify druggable target genes and development of a genomic diagnostic tool for early cancer detection of head and neck tumors.
Kordbacheh completed her Ph.D. at the Australian National University in cancer and vascular biology in 2013. She received her M.Sc. and B.Sc. in cellular and molecular biology from National Institute for Genetic Engineering and Biotechnology and Shiraz University, respectively.